STOCKS TELEGRAPH

Tag: Health Care Stocks

  • Health Care Stocks to Watch: Specialized Eye Care and Public Health Leaders

    Health Care Stocks to Watch: Specialized Eye Care and Public Health Leaders

    Key Takeaways

    • Harrow Inc (HROW) has transitioned into a vertically integrated ophthalmology platform, and HROW stock is entering a sustained profitability phase.
    • Emergent BioSolutions Inc (EBS) has completed a financial turnaround, with EBS stock trading at a valuation discount relative to peers.
    • Specialized eye care and biodefense are becoming essential pillars within health care stocks.
    • Both companies benefit from structural demand drivers: aging demographics and public health preparedness.

    Introduction

    Health care stocks remain a core allocation for long-term investors. In 2026, however, the focus is shifting away from speculative biotech toward companies embedded in essential delivery systems.

    Two themes are emerging as durable growth drivers: precision ophthalmology, pharmaceuticals, and public health preparedness. Aging populations require ongoing vision care, while the opioid crisis and global health risks demand structured national responses.

    Within this landscape, Harrow and Emergent BioSolutions stand out as companies executing disciplined strategies in high-impact segments of the healthcare system.

    What Are Health Care Stocks in Today’s Market?

    Health care stocks span pharmaceuticals, medical devices, biotech, insurers, and service providers. But not all segments offer the same risk profile.

    Speculative biotech firms often depend on binary clinical outcomes. In contrast, infrastructure-oriented healthcare companies generate revenue from established products, recurring prescriptions, or long-term contracts.

    These businesses typically demonstrate:

    • Revenue visibility
    • Policy-supported demand
    • Defensive characteristics during economic downturns
    • Operational leverage at scale

    Ophthalmology drug platforms and biodefense suppliers fall into this more stable category.

    Why Investors Are Targeting Specialized Health Care Segments

    The demand for cataract procedures and chronic dry eye treatment continues to rise as the population ages. Vision restoration and maintenance are non-discretionary medical needs. Companies embedded in ophthalmology clinics benefit from recurring prescription volumes and procedural demand. Over-the-counter naloxone access has expanded nationally. Federal and state programs distribute funding to support harm reduction initiatives.

    This creates consistent demand for opioid reversal products, making parts of the sector less sensitive to traditional consumer spending cycles.

    Governments maintain stockpiles of vaccines and countermeasures for rare but high-impact threats. Multi-year procurement contracts provide revenue stability for select companies. These structural drivers support the long-term investment case for specific health care stocks.

    Key Drivers, Risks, and Industry Trends

    Medicare reimbursement policies and drug pricing reforms can influence margins, especially in branded pharmaceuticals. FDA approval timelines and NDA decisions serve as catalysts for growth. Government budget allocations may create variability in biodefense contract timing.

    Competitive pressure is another risk. New ophthalmic therapies or generic naloxone products could impact pricing power. However, companies with strong distribution networks, vertical integration, and proprietary assets often retain competitive advantages.

    Harrow Inc (HROW)

    Company Overview and Business Model

    Harrow Inc (HROW) has evolved into a vertically integrated ophthalmic pharmaceutical company. Originally rooted in compounding through ImprimisRx, Harrow expanded into FDA-approved branded drugs, creating a broad portfolio serving eye care professionals.

    The company generates revenue through:

    Branded pharmaceutical sales, including VEVYE, IHEEZO, and TRIESENCE. Compounded formulations providing steady cash flow and physician relationships. Royalty and equity stakes in spun-out drug development entities. This “one-stop-shop” model allows Harrow to scale its portfolio using a centralized commercial infrastructure.

    Financial Performance and Strategic Developments

    Harrow recently reported $71.6 million in quarterly revenue, representing 45% year-over-year growth. The company achieved GAAP net income of $1.0 million, marking a transition from prior losses. Adjusted EBITDA reached $22.7 million, reflecting improving margins. Management reaffirmed full-year revenue guidance of $270–$280 million.

    The acquisition of Melt Pharmaceuticals added MELT-300, a non-opioid sedation tablet targeting millions of annual cataract surgeries. The 2026 “OneHarrow” initiative unified operations to enhance efficiency. These developments suggest the company has entered a scalability phase.

    Valuation and Analyst Views

    HROW stock trades at a forward valuation reflecting growth expectations. Analyst consensus currently stands at “Strong Buy,” with average 12-month price targets near the low $70 range.

    Fair value estimates frequently cluster between $70 and $75, indicating potential upside if revenue and margin targets are achieved. Key catalysts include formulary expansion for VEVYE and regulatory progress for MELT-300.

    Investment Suitability

    Harrow may appeal to growth-oriented investors seeking exposure within health care stocks without relying on early-stage clinical speculation. Its integration across ophthalmic care creates embedded demand and operating leverage as scale increases.

    Emergent BioSolutions Inc (EBS)

    Company Overview and Business Model

    Emergent BioSolutions Inc (EBS) has repositioned itself around public health preparedness. Its business is structured around two main segments. The commercial segment centers on NARCAN® Nasal Spray, now available over-the-counter.

    The medical countermeasures segment includes vaccines and treatments supplied primarily through U.S. government contracts. This shift reduced reliance on contract manufacturing and strengthened focus on proprietary assets.

    Financial Performance and Strategic Developments

    Emergent reported quarterly EPS of $1.06, exceeding prior expectations for a loss. Revenue reached $231.1 million, supported by Narcan growth and international countermeasure sales. The company reduced debt by $100 million in early 2026, improving its balance sheet.

    FDA approval of NARCAN multipacks expanded distribution options, while resolving a prior legal matter improved investor sentiment. For the first nine months of 2025, net income exceeded $107 million, marking a sustained return to profitability.

    Valuation and Analyst Views

    EBS stock trades at roughly 8.5x earnings, below broader biotech averages. Analysts maintain a “Buy” consensus, with average price targets in the mid-teens. Valuation models suggest intrinsic value between $11.50 and $13.00, reflecting potential upside if earnings stability continues. Margin expansion toward the 60% range in adjusted gross margins strengthens the turnaround thesis.

    Investment Suitability

    Emergent may suit value-oriented investors seeking a lower-valuation entry within health care stocks. Government-backed contracts and essential opioid reversal demand provide structural support, though investors must monitor policy shifts and competitive dynamics.

    Investment Strategies for Health Care Stocks

    Long-term investors often view health care stocks as portfolio stabilizers. Blending growth exposure through HROW stock with value-oriented positioning in EBS stock can create balanced sector exposure. Monitoring earnings consistency, regulatory milestones, and government contract developments is essential. Position sizing and diversification across healthcare sub-sectors help manage regulatory and policy risk.

    Conclusion

    Health care stocks in 2026 increasingly reward execution over speculation. Harrow Inc (HROW) demonstrates how vertical integration in ophthalmology can create scalable growth and margin expansion. Emergent BioSolutions Inc (EBS) illustrates how disciplined restructuring and focus on essential public health products can restore profitability and investor confidence. As healthcare spending concentrates on specialized delivery and preparedness, companies embedded in system-level demand may continue to play an important role in long-term portfolios.

  • Top 3 Health Care Stocks that can attract investors in 2021

    Top 3 Health Care Stocks that can attract investors in 2021

    Health care is a trillion-dollar industry because health is a global need. A trillion-dollar industry means plenty of companies making millions or billions of dollars annually in the health sector. With the surge of COVID-19, this industry has attracted plethora of investors to invest in healthcare stocks but many of them find it difficult to select the right stock at the right time. This is because many companies have claimed that they are working on vaccines and related products to cope with COVID-19 but only a few of them have found their way to commercialize their products. One should consider the fact that only COVID-19 is not the opportunity to invest in stocks but there are other health issues that demand a great amount of interest. So, investors need to do a large amount of homework before investing in any stock. Here are the few health care stocks that can attract investors in 2021.

    Eli Lilly And Co (NYSE:LLY)

    Eli Lilly and Company (LLY) is an American Pharmaceutical company that focuses on discovering, developing, manufacturing, and commercializing drugs for the cure of various kinds of diseases. The company is doing research and production in many nations and 120 countries are using its products.

    Eli Lilly Generated handsome revenue in 2020 through the sales of its top products which include Trulicity (Diabetes medicine), Basaglar (Insulin product), and Jardiance (Oral Diabetes drug). Trulicity generated $3.6 billion revenue in the first three quarters of 2020 with a rise of 22%. Similarly, Basaglar generated 842$ million revenue with a rise of 5% and Jardiance showed a rise of 24% with 840$ million income.

    The company has got positive results in phase 2 clinical trial of one of its potential drugs for Alzheimer’s disease called donanemab. More than 5 Million Alzheimer’s patients exist in the U.S and still, there is no approved drug for the cure. Still, donanemab has a long way to go for approval but investors can monitor its progress.

    The company reported on Tuesday that its late-stage coronavirus treatment trial which includesBamlanivimab (LY-CoV555) 2800 mg and Etesevimab (LY-CoV016), has reduced the riskof death in serious patients and hospitalization by 70% which is pointing out the bright future of the company and investors in terms of revenue.

    Hence Lilly has a good chance to outperform in the future due to its revenue growth, solid stock price performance, and good cash flow from operations.

    Teladoc Health Inc (NYSE:TDOC)

    Teladoc Health, Inc. (TDOC) is a virtual healthcare company playing a lead role in providing the services of diagnosis, treatment recommendation, and prescription through mobile phones and video consultations. The current pandemic situation is suitable for the company when people do not bother to go out of their homes unnecessarily. The company is getting fame day by day due to its best virtual health care services in remote areas and attracting institutional investors to invest in it.

    Though Teladoc has not revealed the 2020 report but rough estimates show that it has now more than 50 million members, facilitated more than 10 million visits, and generated about 1.1$ billion revenue in 2020 which is almost double than the previous year. Currently, many companies are providing Teladoc’s health care services to their employees which is expecting to grow in the future. Teladoc’s recent acquisition of Lovingo Health is also creating a more positive vibe for investors.

    CVS Health Corp (NYSE:CVS)

    CVS Health Corporation (CVS) is an integrated pharmacy healthcare service provider company. It offers pharmacy benefit management plans, health plans, prescription drug plans, and serves the government as well as private employees of many companies. It possesses nearly 10000 drug stores and1100 Minute Clinics in the U.S.The company is playing a key role in COVID-19 testing and is contributing a lot in the vaccination campaign as it has performed nearly 10 million coronavirus tests and 700,000 vaccinations. The company is currently handling 10% of coronavirus vaccination in the U.S and can vaccinate 25 million people per month.

    CVS is not just relying on COVID vaccination but also fighting against influenza by vaccinating people. The company generated $67 billion in the 3rd quarter of 2020 with a rise of 3.5% in its sales. Moreover, the company possesses more than 23 million health insurance members nationwide. Thanks to Aetna, a CVS subsidiary, which generates more than $18.5 billion per quarter in health insurance fees.

    The company is currently in a good position and has ample profit to sustain its dividend. Its shares are expecting to outperform in 2021 due to active participation in COVID-19 vaccination in the U.S.It can be a  good choice for dividend as well as growth investors.